Clinical Eton Pharma gets FDA nod on Rezipres® for treatment...

Eton Pharma gets FDA nod on Rezipres® for treatment of hypotension in anesthesia settings


Rezipres, an ephedrine HCL (hydrochloride) injectable manufactured by Eton Pharmaceuticals, has been approved by FDA to treat clinically significant hypotension ( low blood pressure) observed in anesthetic locations. Eton’s stock trading remains suspended.
“This innovative sulfite-free formulation has been successfully sold in Europe for years, and we are excited to make it available to U.S. patients shortly,” stated Sean Brynjelsen, CEO of the company.
The investigational medication is under the evaluation of the FDA with a deadline of June 18 specified under PDUFA (Prescription Drug User Fee Act).

Topiramate oral solution, which has a deadline of August 6 set under the Prescription Drug User Fee Act, has also been submitted to get marketing authorization.

+ posts

Latest news

PureTech Launches New CBD Capsule to Challenge Epidiolex

PureTech Health has identified an opening to create a better alternative to Jazz Pharmaceuticals' Epidiolex. The biotech...

Canon Healthcare announces new subsidiary in a bid to expand presence in the U.S.

Japanese tech giant Canon has announced the opening of its second med tech-focused subsidiary in the U.S.,...

Biopharma newcomer Resilience buys AstraZeneca’s Ohio facility

AstraZeneca’s Ohio facility, which was part of the United States covid vaccine production network, has new ownership.

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

Amgen’s KRAS drug gets early FDA approval for lung cancer with specific mutation

On Friday, the United States FDA (Food and Drug Administration) has authorized a medication of Amgen Biopharmaceutical in patients with NSCLC

You might also likeRELATED
Recommended to you